Upregulated PLK1 was one of these targets, and we have previously identified PLK1 inhibitors to be among the most potent anticancer agents in a high-throughput drug screen of seven MPNST cell lines.73 This evidence concerns the gene PLK1 and malignant peripheral nerve sheath tumor.